The findings may open the door for early testing for coronary artery disease risk in patients with lupus, the researchers wrote.

The CardioGENE® lab test, only a concept for the last few years, is now ready for development for practical use as a decision support biomarker test.

BIO-CAT Microbials’ new probiotic shows significant improvement in gastrointestinal symptoms based on a clinical trial.

ACU193 is currently being studied in the Phase 1 INTERCEPT-AD trial designed to assess safety and proof of mechanism of ACU193.

This funding will be used to accelerate product commercialization, expand manufacturing capacity, and seed broader applications of the AgroSpheres AgriCell platform technology.

A biotech company out to corner a new market in the diabetes and weight loss space has recorded its second, and so far largest, raise yet.

Dr. Andrew Fordyce, Dr. Katie Whalen, Robert Coward, and Ross Bartels

The company’s new approach, through a simple blood test, will ultimately accelerate the means of providing effective treatments to the right people at the right time.

Mr. Claiborne brings extensive experience in leadership roles with clinical and commercial stage, publicly traded biopharmaceutical companies.

Dr. Wamhoff is a founder of HemoShear where he co-developed HemoShear’s REVEAL-Tx™ drug discovery platform.

For more than 15 years, the Focused Ultrasound Foundation has been dedicated to advancing the development and adoption of focused ultrasound.

Company plans to submit ONWARD results to both European and U.S. regulatory agencies.